RG7212 / Roche - LARVOL DELTA

TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro. (PubMed, BMC Med) - "Our MR analyses provided genetic evidence supporting TBK1, TNFSF12, RESP18, and GPX3 as druggable genes for ALS treatment. Among the drug candidates targeting the above genes with repurposing opportunities, FDA-approved drug-R788 and AMX served as effective TBK1 inhibitors. The subsequent pharmacological studies validated the potential of R788 and AMX for treating specific ALS subtypes through the inhibition of TBK1 phosphorylation."

Journal • Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders • Inflammation • CD68 • PTPRN • TARDBP • TNFSF12 • TNFSF13